Pipeline overview
Sézary Syndrome
Phase 2 - FDA Fast Track Designation/ EMA PRIME Designation
Preclinical
Phase 1
Phase 2
Phase 3
Mycosis fungoides
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Peripheral T Cell Lymphoma
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Peripheral T Cell Lymphoma
Phase 1b
Preclinical
Phase 1
Phase 2
Phase 3
Unresectable Stage III Non-small Cell Lung Cancer
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Neoadjuvant NSCLC, other
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Neoadjuvant Non-small Cell Lung Cancer
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Cancer (Solid Tumors)
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Acute Myeloid Leukemia
Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
Cancer
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Cancer
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
CD20, tetra-specific ANKET®
Cancer
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3